Table 1 |
||||
|
IL-1 blockade in NLR-related disease |
||||
|
Autoinflammatory disease |
Gene mutated |
Activator |
IL-1 antagonist used |
References |
|
|
||||
|
Muckle-Wells syndrome (MWS) |
NALP3 (CIAS1/NLRP3) |
Anakinra |
||
|
Rilonacept |
[79] |
|||
|
Familial cold autoinflammatory syndrome (FCAS, FCU) |
NALP3 (CIAS1/NLRP3) |
Anakinra |
||
|
Rilonacept |
[79] |
|||
|
Chronic infantile neurological cutaneous and articular syndrome/neonatal onset multisystem inflammatory disease (CINCA/NOMID) [43] |
NALP3 (CIAS1/NLRP3) |
Anakinra |
||
|
Rilonacept |
[79] |
|||
|
Familial Mediteranean fever (FMF) [44] |
MEFV |
Anakinra |
||
|
Pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA) |
PSTPIP1 |
Anakinra |
||
|
Vitiligo [86] |
NALP1 (NLRP1) |
? |
||
|
Gout |
MSU |
Anakinra |
||
|
Pseudogout |
CPPD |
Anakinra |
[60] |
|
|
Hyperimmunoglobulin D syndrome (HIDS) |
Mevalonate kinase |
Anakinra |
||
|
Systemic-onset juvenile idiopathic arthritis (SoJIA) |
Anakinra |
|||
|
Rilonacept |
[79] |
|||
|
Behçet's disease (BD) |
IL-1β polymorphism |
Anakinra |
||
|
Schnitzler's syndrome |
Anakinra |
[77] |
||
|
Blau syndrome (BS)/early onset sarcoidosis |
NOD2 |
Anakinra |
[160] |
|
|
Crohn's disease (CD) |
NOD2 |
Anakinra (Ineffective) |
[158] |
|
|
MEFV (in a proportion of patients) |
? |
|||
|
Other diseases |
||||
|
Hydatidiform mole [87] |
NALP7 (NOD12, NLRP7) |
? |
||
|
Hypertension [54] |
NALP3 |
? |
||
|
Asthma [175] |
NOD1 |
? |
||
|
|
||||
|
IL, interleukin; NLR, NOD-like receptor. |
||||
|
Mathews et al. Arthritis Research & Therapy 2008 10:228 doi:10.1186/ar2525 |
||||